Drug royalties and licensing
These companies earn royalties and milestone payments on drugs that other companies sell.
+42.2%
over 1 year · S&P 500 +11.6%
Key indicators
Health
54 / 100
Fragile
Solid
Price
P/E 25
Cheap
Expensive
Up over 1 year
12 of 16
Volatility
46%
Calm
Choppy
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 16 companies
RPRX
+78.5%
BIIB
+56.9%
HALO
+42.0%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
R
Royalty Pharma
RPRX
32.9%
+78.5%
B
Biogen
BIIB
31.6%
+56.9%
H
Halozyme Therapeutics
HALO
9.7%
+42.0%
P
Protagonist Therapeutics
PTGX
7.3%
+54.3%
L
Ligand Pharmaceuticals
LGND
5.4%
+50.2%
I
Ionis Pharmaceuticals
IONS
4.1%
−60.0%
X
Xencor
XNCR
2.4%
+157.7%
Z
Zymeworks
ZYME
1.5%
+35.5%
N
Novavax
NVAX
1.4%
+18.4%
A
AnaptysBio
ANAB
1.2%
+109.7%
I
Innoviva
INVA
1.1%
−14.6%
O
OPKO Health
OPK
1.0%
+27.3%
E
Enanta Pharmaceuticals
ENTA
0.3%
−7.9%
A
AbCellera Biologics
ABCL
+189.4%
A
Arbutus Biopharma
ABUS
−15.5%
G
Genmab
GMAB
+68.6%